How was the Biotech Financial World in 2015? Unprecedented!

12/04/2016 - 3 minutes

Biotech is still breaking funding records. A new report by EY provides an interesting analysis of how Biotech is doing, globally and in Europe.

ey_biotech_financing_report_2016_europe_usAlthough 2015 was the best for Biotech yet, but there is a slowdown coming – that’s the gist of EY’s recent report: ‘Beyond borders 2016: Biotech financing‘.

This well-known auditing and strategy company looked into the fundraising, number of IPOs, innovation capital and venture capital raised by Biotechs in the US and Europe, to form a better picture of what’s going on in the industry.

For the second year in a row, the total of the sector’s financing reached unprecedented heights. Biotechs raised close to $71Bn in 2015 – way more than the record $56Bn of 2014.

How’s Europe doing?

The financials in 2015 was a record for Europe too, even if only by a slight increase – especially considering the jump in 2014.

Europe saw an increase in venture capital and follow-on offerings,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member